e-learning
resources
Munich 2014
Monday, 08.09.2014
Therapy of thoracic tumours: clinical trials and case series
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Relationship between risk factors for lung cancer and tumor size
B. Palomo Antequera, M. Arias-Guillen, F. Rodríguez Jerez, G. Rubinos Cuadrado, P. Martínez Camblor, J. B. García Casas, P. Casán Clara (Oviedo, Spain)
Source:
International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Session:
Therapy of thoracic tumours: clinical trials and case series
Session type:
Thematic Poster Session
Number:
2732
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Palomo Antequera, M. Arias-Guillen, F. Rodríguez Jerez, G. Rubinos Cuadrado, P. Martínez Camblor, J. B. García Casas, P. Casán Clara (Oviedo, Spain). Relationship between risk factors for lung cancer and tumor size. Eur Respir J 2014; 44: Suppl. 58, 2732
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Association between leptin and risk of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Lung cancer in women: Is it different?
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Evaluation of lung cancer patients with distant organ metastasis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Epidemiological changes of patients with lung cancer over Years
Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer
Year: 2013
Assessment of nutritional status in patients with primary lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Prognostic factors in non-small cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Accelerated lung function decline increases the risk of lung cancer
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Lung diseases infection and risk of lung cancer
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
Metabolomic analysis of serum samples from patients with lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Lung cancer in England: Trends in survival over the duration of the national lung cancer audit
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Weight loss cutoff level as a key variable related to death risk among advanced lung cancer patients
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Does bronchial location of lung cancer influence overall survival?
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept